NCT00545025

Revaccination With Influenza Vaccine GSK1247446A

Safety and Immunogenicity of a Second Vaccination With GSK Biologicals' Influenza Vaccine GSK1247446A in Subjects 18-60 Years Previously Vaccinated in Study 108656

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 243 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The protocol is designed to demonstrate the safety of influenza vaccine GSK1247446A after revaccination.

Detailed description

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Conditions

• Influenza
• Influenza, Human

Interventions

Type	Name	Description
BIOLOGICAL	Influenza Vaccine GSK1247446A	Single dose, Intramuscular injection
BIOLOGICAL	Fluarix™	Single dose, Intramuscular injection

Timeline

• Start date: 2007-10-15
• Primary completion: 2007-12-12
• Completion: 2007-12-12
• First posted: 2007-10-16
• Last updated: 2019-06-26
• Results posted: 2013-05-07

Locations

1 site across 1 country: Belgium